+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


NASH Drugs Market, 2015 - 2025

  • ID: 3412591
  • Report
  • Region: Global
  • 188 Pages
  • Roots Analysis
1 of 4
NASH Is Currently The Third Most Common Factor Leading to Liver Transplants in the US


  • Alnylam Pharmaceuticals
  • Durect
  • ImmuNess
  • Madrigal Pharmaceuticals
  • Perrigo API
  • Therapix Biosciences
  • MORE

The NASH Drugs Market, 2015-2025 report provides a comprehensive study on the current landscape and the future outlook of the evolving pipeline of molecules in this area. With an expanding NAFLD and NASH population worldwide, there is a growing need for development of therapeutics in this disease area.

NASH is gradually emerging as the leading cause of liver transplants. While the field has garnered interest of several companies, there are no approved therapies till date. It is important to stress that the development pipeline of NASH has several promising candidates that are likely to result in many commercial success stories in the foreseen future.

Amongst other elements, the report elaborates on the new diagnostic solutions being developed and the upcoming opportunities for different stakeholders. As pharmaceutical companies continue to initiate and expand their research programs in this area, one of the key objectives outlined for this report is to understand the future potential of the market. This is done by analyzing:

  •  The epidemiology, patient population and staging of NASH in different geographies.
  •  The NASH pipeline in terms of phase of development, type of molecule, route of administration and mechanism of action.
  •  The likely evolution in the rate of diagnosis, drug treated patient population and the likely price of the drugs.
  •  The associated constraints, in terms of undefined pathogenesis and the unavailability of non-invasive diagnostic tests, and the initiatives being carried out by the companies to overcome these.

The study provides a detailed scenario analysis to estimate the market forecast for the period till 2025. The research, analysis and insights presented in this report include potential sales of the drugs in late stages of development and expected to launch by 2025. Our opinions and insights, presented in this study, were influenced by the discussions that we conducted with experts in this area. These included senior representatives at BiOrion Technologies, Phenex Pharmaceuticals, Tobira Therapeutics, Verlyx Pharmaceuticals and Connexios.

All actual figures have been sourced and analyzed from publicly available information and discussions with industry experts. The figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights

  •  During the course of our study, we identified over 50 molecules. Of these, two molecules (Lipaglyn by Zydus Cadila and OCA by Intercept Pharmaceuticals) are in phase 3 clinical studies. Nearly 37% of the pipeline is captured by molecules in phase 2 and 22% in phase 1. Additionally, 35% of the molecules are in preclinical / discovery phase, demonstrating the strong market potential of this field.
  •  Amongst several companies expanding in this domain, Intercept Pharmaceuticals is expected to launch INT 747 in the US and EU5 countries in 2017/2018. Subsequently, Genfit (GFT505), Gilead Sciences (GS-6624), Conatus Pharmaceuticals (Emricasan), Galmed Pharmaceuticals (Aramchol) and Raptor Pharmaceuticals (RP103) are expected to complete the clinical trials of their respective molecules in the coming years, sustaining the growth momentum.
  •  Lack of competent diagnostic tests has led to a poor diagnosis rate and management of NASH so far. Liver biopsy is currently the gold standard to validate the presence of NASH. We believe that merely 5% - 10% of the total patients suffering from the disease are actually being diagnosed in the US and the EU 5 countries. In addition to developments of tests to diagnose NASH, many small and mid-sized firms are now developing companion diagnostics alongside their NASH drug candidates.
  •  The market is fragmented with several start-ups actively involved in this area. Examples (in alphabetical order) include Cerenis Therapeutics, DS Biopharma, Galectin Therapeutics, Immuron, Islet Sciences, Matinas BioPharma, Metabolic Solutions, Naia Pharmaceuticals, Nimbus Therapeutics, Verva Pharmaceuticals, ViroBay and Zafgen.
  •  The overall market is likely to be influenced by several parameters such as diagnosis rate, drug penetration and the likely price of the drugs. We expect the market to witness an aggressive growth rate of close to 90%, emerging as a multi-billion dollar market by 2025. However, with successful reimbursement practices and launch in wider markets, the overall opportunity could be much higher.
Note: Product cover images may vary from those shown
2 of 4


  • Alnylam Pharmaceuticals
  • Durect
  • ImmuNess
  • Madrigal Pharmaceuticals
  • Perrigo API
  • Therapix Biosciences
  • MORE

1. Preface
1.1. Scope Of The Report
1.2. Research Methodology
1.3. Chapter Outlines

2. Executive Summary

3. Introduction
3.1. Context And Background
3.2. The Concept Of Nash
3.3. Target Patient Population
3.4. Pathogenesis Of Nash
3.5. Epidemiology
3.6. Animal Models For Nash
3.7. Clinical Trial Designs And End Points
3.8. Regulatory Initiatives

4. Treatment Options And Diagnostic Solutions
4.1. Context And Background
4.2. Treatment Options For Nash
4.2.1. General Recommendations
4.2.2. Pharmacological Interventions
4.2.3. Natural Products For The Treatment Of Nash
4.3. Diagnostic Solutions

5. Market Dynamics
5.1. Chapter Overview
5.2. Key Growth Drivers
5.2.1. Growing Worldwide Prevalence Of Obesity And Diabetes
5.2.2. Increase In Research And Development Initiatives
5.2.3. Promising Late Stage Molecules
5.3. Challenges
5.3.1. Lack Of Understanding Of Pathophysiology Of Nash
5.3.2. Incompetent Diagnostic Tools For Nash

6. Market Overview
6.1. Context And Background
6.2. Pipeline Of Drugs
6.3. Pipeline Analysis
6.3.1. Distribution By Phase Of Development
6.3.2. Distribution By Type Of Molecule
6.3.3. Distribution By Route Of Administration

7. Upcoming Nash Drugs: Detailed Profiles
7.1. Context And Background
7.2. Lipaglyn, Saroglitazar (Zyh1), Zydus-Cadila
7.2.1. Drug Overview
7.2.2. Background
7.2.3. Mechanism Of Action
7.2.4. Development Status
7.2.5. Key Clinical Trial Results
7.2.6. Patent Portfolio
7.3. Int-747 (Obeticholic Acid (Oca))/ Dsp-1747, Intercept Pharmaceuticals
7.3.1. Drug Overview
7.3.2. Background
7.3.3. Mechanism Of Action
7.3.4. Development Status
7.3.5. Key Clinical Trial Results
7.3.6. Manufacturing
7.3.7. Patent Portfolio
7.3.8. Collaborations
7.4. Emricasan (Idn-6556), Conatus Pharmaceuticals
7.4.1. Drug Overview
7.4.2. Mechanism Of Action
7.4.3. Development Status
7.4.4. Key Clinical Trial Results
7.4.5. Manufacturing
7.4.6. Collaborations
7.5. Gft505, Genfit
7.5.1. Drug Overview
7.5.2. Background
7.5.3. Mechanism Of Action
7.5.4. Development Status
7.5.5. Key Clinical Trial Results
7.5.6. Patent Portfolio
7.5.7. Collaborations
7.6. Cenicriviroc (Cvc), Tobira Therapeutics
7.6.1 Drug Overview
7.6.2. Background
7.6.3. Mechanism Of Action
7.6.4. Development Status
7.6.5. Key Clinical Trial Results
7.6.6. Manufacturing
7.6.7. Collaborations
7.7. Aramchol, Galmed Pharmaceuticals
7.7.1. Drug Overview
7.7.2. Background
7.7.3. Mechanism Of Action
7.7.4. Development Status
7.7.5. Key Clinical Trial Results
7.7.6. Manufacturing
7.7.7. Collaborations
7.8. Simtuzumab (Gs-6624), Gilead Sciences
7.8.1. Drug Overview
7.8.2. Mechanism Of Action
7.8.3. Development Status
7.8.4. Key Clinical Trial Results
7.8.5. Manufacturing
7.8.6. Patent Portfolio
7.8.7. Collaborations
7.9. Procysbi (Rp103), Raptor Pharmaceuticals
7.9.1. Drug Overview
7.9.2. Background
7.9.3. Mechanism Of Action
7.9.4. Development Status
7.9.5. Key Clinical Trial Results
7.9.6. Manufacturing
7.9.7. Patent Portfolio
7.9.8. Collaborations
7.10. Remogliflozinetabonate (Remo), Islet Sciences / Bhv Pharma
7.10.1. Drug Overview
7.10.2. Background
7.10.3. Mechanism Of Action
7.10.4. Development Status
7.10.5. Key Clinical Trial Results
7.10.6. Patent Portfolio
7.10.7. Collaborations

8. Market Sizing And Opportunity Analysis
8.1. Chapter Overview
8.2. Important Parameters And Key Assumptions
8.2.1. Target Patient Population
8.2.2. Diagnosis Rate
8.2.3. Drug Penetration Rate
8.2.4. Price Of The Drug
8.3. Scenario Analysis: Description And Methodology
8.4. Overall Nash Market, 2015-2025

9. Company Profiles
9.1. Chapter Overview
9.2. Conatus Pharmaceuticals
9.2.1. Company Overview
9.2.2. Financial Performance
9.2.3. Nash Drugs Portfolio
9.2.4. Partnerships
9.2.5. Future Outlook
9.3. Galmed Pharmaceuticals
9.3.1. Company Overview
9.3.2. Financial Performance
9.3.3. Nash Drugs Portfolio
9.3.4. Partnerships
9.3.5. Future Outlook
9.5. Genfit
9.5.1. Company Overview
9.5.2. Financial Performance
9.5.3. Nash Drugs Portfolio
9.5.4. Partnerships
9.5.5. Future Outlook
9.6. Gilead Sciences
9.6.1. Company Overview
9.6.2. Financial Performance
9.6.3. Nash Drugs Portfolio
9.6.4. Partnerships
9.6.5. Future Outlook
9.7. Intercept Pharmaceuticals
9.7.1. Company Overview
9.7.2. Financial Performance
9.7.3. Nash Drugs Portfolio
9.7.4. Partnerships
9.7.5. Future Outlook
9.8. Novo Nordisk
9.8.1. Company Overview
9.8.2. Financial Performance
9.8.3. Nash Drugs Portfolio
9.8.4. Future Outlook
9.9. Raptor Pharmaceuticals
9.9.1. Company Overview
9.9.2. Financial Performance
9.9.3. Nash Drugs Portfolio
9.9.4. Partnerships
9.9.5. Future Outlook
9.10. Zydus Cadila
9.10.1. Company Overview
9.10.2. Financial Performance
9.10.3. Nash Drugs Portfolio

10. Conclusion
10.1. Nash: Emerging As The Next Epidemic
10.2. Lifestyle Interventions: A Solution To Reduce Severity Of The Disease
10.3. Diagnosis Of Nash Remains A Challenge
10.4. With A High Unmet Need; Nash Is Anticipated To Be A Multi-Billion Market

11. Interview Transcripts
11.1. Chapter Overview
11.2. Biorion Technologies (Herman Steen, Ceo)
11.3. Phenex Pharmaceuticals (Dr. Claus Kremoser, Ceo)
11.4. Tobira Therapeutics (Laurent Fischer, Ceo And Andrew Mckibben, Director, Finance & Corporate Development)
11.5. Verlyx Pharma (Dr. Pierre Falardeau, Ceo)
11.6. Connexios (Shobhavijayaraghavan, Vp Business Development)

12. Appendix1: Tabulated Data

13. Appendix 2: List Of Companies And Organizations

List of Figures

Figure 3.1 Spectrum of Non Alcoholic Fatty Liver Disease
Figure 3.2 NAFLD: Classification
Figure 3.3 Chronology of the Pace of Research and Development for NASH
Figure 3.4 NAFLD and NASH: Pathogenesis
Figure 3.5 Prevalence of NASH
Figure 3.6 Prevalence of NASH in the US
Figure 3.7 Design and End-points for Clinical Trials of NASH
Figure 5.1 NASH Drugs Market: Key Market Drivers and Restraints
Figure 5.2 Rise in Overweight and Obesity Rate, 1980-2013
Figure 5.3 Diabetes: Worldwide Prevalence and Diagnosis (Million)
Figure 5.4 Diabetes: Prevalence by Regions /Countries (2014), Million
Figure 5.5 Diabetes: Diagnosed Cases by Regions /Countries (2014), Million
Figure 6.1 NASH Drugs: Distribution by Phase of Development
Figure 6.2 NASH Drugs: Distribution by Type of Molecule
Figure 6.3 NASH Drugs: Distribution by Route of Administration
Figure 7.1 Lipaglyn (Saroglitazar): Development Timeline
Figure 7.2 INT-747: Mechanism of Action
Figure 7.3 INT-747: Design of Phase III REGENERATE Trial
Figure 7.4 GFT505: Mechanism of Action
Figure 8.1 NASH Future Market Scenarios
Figure 8.2 Overall NASH Drugs Market, 2018- 2025 (USD Million)
Figure 8.3 NASH Drugs Market: Distribution by Region, 2025 (USD Million)
Figure 8.4 Timeline: Launch of NASH Molecules
Figure 8.5 NASH Drugs Market: Indicative Distribution by Drugs: 2020, 2025
Figure 8.6 Market Scenarios, Comparative Positioning (USD Billion)
Figure 9.1 Conatus Pharmaceuticals: NASH Drugs Pipeline
Figure 9.2 Galmed Pharmaceuticals: NASH Drugs Pipeline
Figure 9.3 Genfit: Development History
Figure 9.4 Genfit: Revenues, 2010-2014 (EUR Million)
Figure 9.5 Genfit: Distribution of Revenues, 2014 (EUR Million)
Figure 9.6 Genfit: NASH Drugs Pipeline
Figure 9.7 Gilead Sciences: Net Revenues, 2010 – H1 2015 (USD Billion)
Figure 9.8 Gilead Sciences: Distribution of Revenues, 2014 (USD Million)
Figure 9.9 Gilead Sciences: NASH Drugs Pipeline
Figure 9.10 Intercept Pharmaceuticals: Revenues, 2011- H1 2015 (USD Million)
Figure 9.11 Intercept Pharmaceuticals: NASH Drugs Pipeline
Figure 9.12 Novo Nordisk Revenues, 2010 - H1 2015 (DKK Million)
Figure 9.13 Novo Nordisk Revenues: Distribution by Business Segment, 2014 (DKK Billion)
Figure 9.14 Novo Nordisk: NASH Drugs Pipeline
Figure 9.15 Raptor Pharmaceuticals: Revenues, 2013- H1 2015 (USD Million)
Figure 9.16 Raptor Pharmaceuticals: NASH Drugs Pipeline
Figure 9.17 Zydus Cadila: Revenues, 2010-2014 (INR Billion)
Figure 9.18 Zydus Cadila: Revenues by Geographies, 2014 (INR Billion)
Figure 9.19 Zydus Cadila: NASH Drugs Pipeline
Figure 10.1 NASH Drugs Market (USD Million), 2018, 2020 and 2025

List of Tables

Table 3.1 Various Animal Models for the Study of NASH
Table 3.2 Important Definitions and Specifications for NASH Clinical Studies
Table 3.3 Pre-fibrotic NAFLD/ NASH: Diagnostic Categories and Associated Histologic Lesions
Table 4.1 Recommended Nutritional Guidelines for NAFLD/ NASH
Table 4.2 Plant Extracts Used for the Treatment of NASH
Table 4.3 Polyherbal Medications for Management of NASH
Table 4.4 Phytochemicals for Treatment of NASH
Table 4.5 NASH: Non-invasive Imaging Diagnostic Methods
Table 6.1 NASH: Pipeline of Drugs
Table 7.1 NASH: Molecules in Late Stage of Development
Table 7.2 Saroglitazar: Clinical Trials
Table 7.3 Saroglitazar: Patent Portfolio
Table 7.4 FLINT Trial: Key Baseline Charcateristics
Table 7.5 INT-747: Research and Development Expenses
Table 7.6 INT-747: Patent Portfolio
Table 7.7 Emricasan: Phase 1 Clinical Trial Summary
Table 7.8 Emricasan: Clinical Trial Results
Table 7.9 GFT505: Clinical Trials
Table 7.10 CVC: Clinical Trials
Table 7.11 CVC: Patent Portfolio
Table 7.12 Aramchol: Clinical Trials
Table 7.13 Aramchol: Important Paramters of ARREST Study
Table 7.14 Aramchol: Completed Clinical Trials
Table 7.15 Simtuzumab: Clinical Trials
Table 7.16 Simtuzumab: Patent Portfolio
Table 7.17 RP103: Clinical Trials
Table 7.18 RP103: Treatment Regimen
Table 7.19 RP103: Patent Portfolio
Table 7.20 Remogliflozin etabonate: Clinical Development Overview
Table 7.21 Remogliflozin etabonate: Patent Portfolio
Table 8.1 Opportunity Analysis: Target Patient Population
Table 8.2 Opportunity Analysis: Diagnosis Rate
Table 8.3 Opportunity Analysis: Drug Penetration Rates
Table 8.4 Opportunity Analysis: Price of the Drug
Table 9.1 INT-747: Planned 2015 Milestones
Table 12.1 Rise in Overweight and Obesity Rate, 1980-2013
Table 12.2 Diabetes: Worldwide Prevalence and Diagnosis (Million)
Table 12.3 Diabetes: Prevalence by Regions/ Countries (2014), Million
Table 12.4 Diabetes: Diagnosed Cases by Regions/ Countries (2014), Million
Table 12.5 NASH Drugs: Distribution by Phase of Development
Table 12.6 NASH Drugs: Distribution by Type of Molecule
Table 12.7 NASH Drugs: Distribution by Route of Administration
Table 12.8 Overall NASH Drugs Market, 2018-2025 (USD Million)
Table 12.9 NASH Drugs Market: Indicative Distribution by Drugs: 2020, 2025
Table 12.10 Market Scenarios, Comparative Positioning (USD Billion)
Table 12.11 Genfit: Revenues, 2010-2014 (EUR Million)
Table 12.12 Genfit: Distribution of Revenues, 2014 (EUR Billion)
Table 12.13 Gilead Sciences: Net Revenues, 2010 – H1 2015 (USD Billion)
Table 12.14 Gilead Sciences: Distribution of Revenues, 2014 (USD Million)
Table 12.15 Intercept Pharmaceuticals: Revenues, 2011- H1 2015 (USD Million)
Table 12.16 Novo Nordisk Revenues, 2010 – H1 2015 (DKK Million)
Table 12.17 Novo Nordisk Revenues: Distribution by Business Segment, 2014 (DKK Billion)
Table 12.18 Raptor Pharmaceuticals: Revenues, 2013-H1 2015 (USD Million)
Table 12.19 Zydus Cadila: Revenues, 2010-2014 (INR Billion)
Table 12.20 Zydus Cadila: Revenues by Geographies, 2014 (INR Billion)
Table 12.21 Nash Drugs Market (USD Million), 2018, 2020, and 2015

Note: Product cover images may vary from those shown
3 of 4


4 of 4


  • Alnylam Pharmaceuticals
  • Durect
  • ImmuNess
  • Madrigal Pharmaceuticals
  • Perrigo API
  • Therapix Biosciences
  • MORE

Research Methodology

Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:
- Annual reports
- Investor presentations
- SEC filings
- Industry databases
- News releases from company websites
- Government policy documents
- Industry analysts’ views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines:

Chapter 2 provides an executive summary of the insights captured in our research. The summary offers a high level view on where the market for NASH drugs is headed in the mid to long term.

Chapter 3 provides a general introduction to NASH, underlying the basic concepts of this disease area. In this section, we have briefly discussed the causes, classification, symptoms and different stages of NASH. Additionally, we have highlighted the historical evolution, pathogenesis, prevalence and the target patient population of NASH.

Chapter 4 gives an overview of the treatment and diagnostic solutions associated with NASH. We have discussed, in detail, the general recommendations, pharmacological interventions and natural remedies for treatment of the disease. This chapter also covers the non-invasive means of evaluating and staging NAFLD patients.

Chapter 5 summarises the market dynamics of NASH. It highlights the key drivers and restraints likely to influence the evolution of this market. In addition, it also covers the various research and development initiatives which have been takenby different stakeholders in this domain.

Chapter 6 provides a comprehensive market overview highlighting the therapeutics being developed to treat NASH. It offers an elaborate analysis of the drugs under development with their phase of development, route of administration, type of molecule and the mechanism of action.

Chapter 7 presents detailed profiles of the drugs in advanced stages of development.Each profile provides the drug overview, background, mechanism of action, current development status, key clinical trials, respective results andother recent developments associated with the drug.

Chapter 8 offersa scenario based approach to determine the overall market opportunity for NASH drug developers in the coming decade. The analysis highlights the likely evolution of important parameters such as the diagnosis rate, drug penetration rates and annual pricing. In addition, we have also presented an indicative distribution of the overall market amongst the different drugs likely to be launched in the near future..

Chapter 9 provides detailed company profiles of the leading players in the market. Each company profile includes information such as financial performance, product portfolio, recent collaborations and future outlook.

Chapter 10 summarises the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapter 11 is a collection of interview transcripts of the discussions which were held during the course of this study. For the purposes of this study, we held discussions with seniormost representatives at BiOrion Technologies, Phenex Pharmaceuticals, Tobira Therapeutics, Verlyx Pharmaceuticals and Connexios.

Chapter 12 is an appendix which provides tabulated data and numbers for all the figures provided in the report.

Chapter 13 is an appendix which provides the list of companies mentioned in the report.

Note: Product cover images may vary from those shown
5 of 4

- Alnylam Pharmaceuticals
- American Diabetes Association
- Arresto Biosciences
- AstraZeneca
- BiOrion Technologies
- BHV Pharma
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Cadila Healthcare
- Cerenis Therapeutics
- Conatus Pharmaceuticals
- Connexios
- DS Biopharma
- Durect
- Encode Pharmaceuticals
- Enanta Pharmaceuticals
- Endonovo Therapeutics
- Exalenz Bioscience
- Fournier
- Galectin Therapeutics
- Galmed Pharmaceuticals
- Genfit
- Gilead Sciences
- Idun
- Immune Pharmaceuticals
- ImmuNess
- Immuron Ltd.
- Intercept Pharmaceuticals
- Isis Pharmaceuticals
- Islet Sciences
- Johns Hopkins University
- Kadmon
- Kissei Pharmaceuticals
- KrisaniBio
- Kyorin Pharmaceutical
- LibbsFarmaceutica
- Ligand
- Madrigal Pharmaceuticals
- Matinas BioPharma
- McGill University
- Medicinova
- Merck
- Metabolic Solutions
- Mochida Pharmaceutical Company
- Naia Pharmaceuticals
- National Institute of Diabetes and Digestive and Kidney Diseases
- NAFLD Clinical Research Network
- Niigata University
- NGM Biopharmaceuticals
- Nimbus Therapeutics
- Novo Nordisk
- One Way Liver Genomics SL
- Perrigo API
- Pfizer
- Pierre Fabre
- Phenex Pharmaceuticals
- Raptor Pharmaceuticals
- Regulus Therapeutics
- Sanofi-Aventis
- SATT Sud Est
- Seattle Children's Research Institute
- Servier
- Shire
- Sumitomo Dainippon Pharma
- Taiwan Pharmaceuticals
- Therapix Biosciences
- Tobira Therapeutics
- University of Arizona
- University of California
- University of Perugia
- Verlyx Pharma
- Verva Pharmaceuticals
- Viking Therapeutics
- ViroBay
- XTuit Pharmaceuticals
- Zafgen
- Zydus Cadila

Note: Product cover images may vary from those shown